

10/536636

ATTORNEY DOCKET NO.: 08830-0342US1

1013 Rec'd PCT/PTO 27 MAY 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
ACTING AS THE DESIGNATED/ELECTED OFFICE

In re: Patent application of: Gillian Lindy DURRANT

Appl. No.: Not Yet Assigned
(International Application No. PCT/GB2003/005163)

Filed: (International Filing Date: 26 November 2003 (26.11.2003))

For: CD55-INTERACTION PARTNERS AND THE USES THEREOF

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450
ATTN: DO/EO/US

INFORMATION DISCLOSURE STATEMENT

The present application is a 35 U.S.C. § 371 of PCT/GB2003/005163. Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, submitted herewith in duplicate as a substitute PTO Form 1449 listing the references cited in the Search Report in the international phase. A copy of the International Search Report is enclosed.

It is believed that copies of the references have been or will be forwarded by the International Search Authority. The Examiner is encouraged to contact the undersigned if reference copies have not been received.

CERTIFICATE OF MAILING UNDER 37 C.F.R. 1.10	
EXPRESS MAIL Mailing Label Number: EV320480848US	
Date of Deposit: May 27, 2005	
I hereby certify that this correspondence, along with any paper referred to as being attached or enclosed, and/or fee, is being deposited with the United States Postal Service, "EXPRESS MAIL-POST OFFICE TO ADDRESSEE" service under 37 C.F.R. 1.10, on the date indicated above, and addressed to: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.	
	
Signature of person mailing page:	
KAREN M. SPINA	
Type or print name of person	

10/536636

US NAT'L PHASE OF PCT/GP 03/005163

ATTORNEY DOCKET NO.: 08830-0342US1

JC13 Rec'd PCT/PTO 27 MAY 2005

The Examiner is respectfully requested to review the items listed on the substitute PTO Form 1449 and make them of record in the instant application as required by M.P.E.P. §609. It is requested that the Examiner initial the enclosed duplicate substitute PTO Form 1449, and return one copy to the undersigned.

This Information Disclosure Statement should not be construed as a representation that the cited references are material or that more relevant prior art does not exist.

This Information Disclosure Statement is being submitted concurrently with the filing of the above-referenced application. Therefore, no certification, petition or fee is required. However, should a fee be due, authorization is hereby provided to charge Deposit Account No. 50-0573.

Respectfully submitted,

GILLIAN LINDY DURRANT

BY


DANIEL A. MONACO
Registration No. 30,480
DRINKER BIDDLE & REATH LLP
One Logan Square
18th and Cherry Streets
Philadelphia, PA 19103-6996
TEL.: (215) 988-3312
FAX: (215) 988-2757
Attorney for Applicant

10/536636
JC13 Rec'd CT/PTO 27 MAY 2009

Sheet 1 of 1

SUBSTITUTE FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 08330-0342US1	APPLICATION NO. Not Yet Known (I.A. PCT/GB2003/005163)
INFORMATION DISCLOSURE STATEMENT				APPLICANT: Gillian Lindy Durrant	
				FILING DATE (I.A. 26 November 2003)	GROUP Not Yet Known

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION <u>YES</u> <u>NO</u>
	A	WO 98/06838	19 Feb 1998	PCT	C12N	15/12	
	B	WO 00/37489	29 June 2000	PCT	C07K	14/00	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

C	Baldwin et al., "Monoclonal Antibody 791T/36 For Tumor Detection And Therapy For Metastases", <i>Symposium On Fundamental Cancer Research</i> 36:437-455 (1983)	
D	Spendlove et al., "Mapping The Binding Site Of A Novel Antibody To SCR-1 And 2 of CD55", <i>Immunology</i> 98(1): 101 (1999)	
E	Bradley et al., "A Monoclonal Antibody Directed Against SCR1-2 Of Complement Control Protein, CD55 Enhances C3 Deposition And Tumor Cell Lysis", <i>British Journal Of Cancer</i> 88 (Supplement 1): S39 (2003)	
F	Pimm et al., "A Bispecific Monoclonal Antibody Against Methotrexate And A Human Tumor Associated Antigen Augments Cytotoxicity Of Methotrexate-Carrier Conjugate", <i>British Journal Of Cancer</i> 61(4): 508-513 (1990)	
G	Spendlove et al., "Decay Accelerating Factor (CD55): A Target For Cancer Vaccines?", <i>Cancer Research</i> 59(10): 2282-2286 (1999)	
H	Hamann et al., "Characterization Of The CD55 (DAF)-Binding Site On The Seven-Span Transmembrane Receptor CD97", <i>European Journal Of Immunology</i> 28(5): 1701-1707 (1998)	

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	